A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
about
Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital wartsBiomarkers of head and neck cancer, tools or a gordian knot?Combined p53-related genetic variants together with HPV infection increase oral cancer riskRole of histological findings and pathologic diagnosis for detection of human papillomavirus infection in menA note from history: Landmarks in history of cancer, part 7.Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays.Use of the normalized absorbance ratio as an internal standardization approach to minimize measurement error in enzyme-linked immunosorbent assays for diagnosis of human papillomavirus infectionHuman papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunityHumoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA.Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay.Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Detection and quantitation of human papillomavirus by using the fluorescent 5' exonuclease assayPrevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.Detection of infectious organisms in archival prostate cancer tissues.Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinomaEnhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirusGenetic variants of NOXA and MCL1 modify the risk of HPV16-associated squamous cell carcinoma of the head and neck.Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sitesHuman papillomavirus seropositivity and subsequent risk of HIV acquisition in rural South African womenMicroRNA variants increase the risk of HPV-associated squamous cell carcinoma of the oropharynx in never smokers.Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancerChimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responsesPapillomaviruses: Viral evolution, cancer and evolutionary medicineEfficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein.Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.How will HPV vaccines affect cervical cancer?Prospective study on cervical neoplasia: presence of HPV DNA in cytological smears precedes the development of cervical neoplastic lesions.Modifying effect of MDM4 variants on risk of HPV16-associated squamous cell carcinoma of oropharynxImmunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection.Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected WomenBinding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells.Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor
P2860
Q24645760-878F3BF4-2402-452A-A9BF-BC0FC15C893EQ26784289-7A5AF7B2-A69D-4EDB-8395-2649C55631E0Q28397067-0BBA5951-08FE-4111-9C27-F4C607CB54CCQ30299997-1CCD3CB6-501A-4349-ABC5-09F774C85F41Q30931923-5BB8E1B5-B389-4FCA-B73F-F3348903B3F5Q33186315-27969AEC-3174-4283-925E-1F0B523E6FCBQ33704870-C4D7C62B-CEB0-4B38-BF19-59CA0CD8FDFEQ33785841-5AC1B32F-101F-4FB5-8823-DFF5EA371F85Q33788885-DBF50A85-9D5C-44F0-8828-4B27E2C6FB8AQ33797578-9F8CD23B-02EA-4614-B688-267B88202D15Q33908917-2BF1F885-6259-4982-8558-1899AF2AF075Q33936598-F798143A-C117-453E-AFA8-53CFF04622C0Q33943463-9274B2AF-D031-4708-A36F-492A7023CAFBQ33953881-2E2A2CAF-2FC8-40A5-B52F-0625405378E7Q33959085-87373095-B469-4EAE-A5D2-A22B57B5FDFEQ33974260-48BAC16B-381B-42DC-BFC3-CA0687CBBDD5Q34045208-65F6BDC7-A205-448C-8381-4D7625833A9BQ34134333-EC000BF7-2A5B-4EBB-B7D8-BF8BDB6A6687Q34203433-27791FCD-09F1-4CD1-B6E1-3CDAB366CBD5Q34252925-6BF974CE-2579-4051-9906-6A6C3AE9BA64Q34367405-AD7EB670-106E-4672-8076-A159F03E5A70Q34551969-3B239572-22BB-4625-A54C-D1C97FECB27DQ34606965-14F854B7-395B-4FD7-8AF9-0213A7122DF4Q34995733-13D2619B-2546-434C-979C-17A59DC34915Q35034741-E5A2DAB6-5A3E-4591-90C3-6F461693DFF3Q35155333-6BBC4A7F-3FE5-4C10-8A06-497E8014A0D9Q35155632-E6D8DF07-CBFB-42DB-98EC-F2A7FEF64C15Q35166924-42684C83-CAED-403F-933E-C086A3A4DA3EQ35221177-66D1D5DD-5A9C-403D-B96A-C0C8F70394A8Q35228223-E2BF93B8-7F6C-4476-8F7C-D8C6AE75C22CQ35228978-4B68F988-A3B9-409C-A8F5-B977BEAA8654Q35235035-D3E9C880-E920-4FB3-97CA-9A6FF6FA74DBQ35530610-B598303E-5674-491E-8E94-A5DEEB9D1F22Q35541775-863670B2-4875-4221-8C98-AFC120A33523Q35562265-8220DB8C-D5D5-4E55-B4C7-EE45CB1C41BFQ35566274-B9791C5C-2579-4271-9732-E5809D00C072Q35743769-72AAA7FB-C96C-4DF9-B951-948A2AAB7D14Q35839345-8C79BCCF-5F6B-4EC1-82FC-C665C87A9669Q35840539-87ED0AFC-F7C6-47A4-A3C1-1A2CF6544DE8Q35845291-EFB7A130-CC95-4F55-9C92-A3DF2A549935
P2860
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1994
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A virus-like particle enzyme-l ...... human papillomavirus type 16.
@en
A virus-like particle enzyme-l ...... human papillomavirus type 16.
@nl
type
label
A virus-like particle enzyme-l ...... human papillomavirus type 16.
@en
A virus-like particle enzyme-l ...... human papillomavirus type 16.
@nl
prefLabel
A virus-like particle enzyme-l ...... human papillomavirus type 16.
@en
A virus-like particle enzyme-l ...... human papillomavirus type 16.
@nl
P2093
P2860
P356
P1476
A virus-like particle enzyme-l ...... human papillomavirus type 16.
@en
P2093
C M Wheeler
J T Schiller
N L Hubbert
R Kirnbauer
T M Becker
P2860
P304
P356
10.1093/JNCI/86.7.494
P407
P577
1994-04-01T00:00:00Z